Trial results

Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema

NCT07817251 on ClinicalTrials.gov · last registry update 2026-09-30

A small phase 3 — 210 participants, against a typical 424. Due to report 9 June 2027, alongside 42 other tracked readouts that quarter. Primary outcome, as filed: Number of treatment emergent adverse events (TEAEs). Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 2 times since then.

Status

RECRUITING

Phase

P3

Drug

semaglutide

Ozempic, Rybelsus, Wegovy

Sponsor

Novo Nordisk A/S

Sponsor type

Industry

Enrollment

210

Started

2026-09-16

Primary completion

2027-06-09 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Number of treatment emergent adverse events (TEAEs)

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.